Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2025 | $77.00 | Buy → Sell | CFRA |
| 1/7/2025 | Hold → Buy | Argus | |
| 11/12/2024 | $111.00 → $110.00 | Equal-Weight → Overweight | Morgan Stanley |
| 11/8/2024 | $107.00 | Neutral → Buy | BofA Securities |
| 11/7/2024 | $109.00 | Hold → Buy | Vertical Research |
| 9/11/2024 | $116.00 → $117.00 | Outperform | Oppenheimer |
| 9/3/2024 | $109.00 → $120.00 | Neutral → Outperform | Mizuho |
| 7/22/2024 | $95.00 → $115.00 | Hold → Buy | Stifel |
Joint venture Alpha Bio will use IFF's proprietary Designed Enzymatic Biomaterials™ technology to provide high-performance, sustainable alternatives to fossil-based ingredients IFF (NYSE:IFF) and Kemira announced the formation of Alpha Bio, a joint venture aimed at commercial-scale production of renewable biobased materials. With an investment of approximately €130 million, the Alpha Bio facility will start production in late 2027, converting up to 44,000 MT of plant sugars to bioproducts, including high-performance biopolymers for use in various applications, such as home and personal care and industrial solutions. Alpha Bio's production will use IFF's Designed Enzymatic Biomaterial™ (DEB
Global Leading Excipient Supplier to Highlight Innovations in Oral Disintegrating Tablets, Controlled Release Formulations, and Low-Nitrite Solutions IFF (NYSE:IFF) Pharma Solutions will showcase its cutting-edge excipient technologies at CPHI Japan 2025. The IFF Pharma Solutions team will highlight its innovations in oral disintegrating tablets (ODTs), controlled-release formulations, and novel complex formulations at booth 5K-21, Tokyo Big Sight East Halls 4-6, April 9-11. "IFF Pharma Solutions is committed to redefining drug delivery through material science innovation," said Frank Zhao, commercial leader, IFF Pharma Solutions, Asia Pacific. "At CPHI Japan, we will showcase technologie
New studies reveal that the three-strain Bacillus probiotic can better protect weaned piglets against diverse health challenges. SINGAPORE, March 10, 2025 /PRNewswire/ -- IFF (NYSE:IFF) today announced the extension of their three-strain Bacillus probiotic, Enviva® PRO, to pigs. By incorporating IFF's probiotic into their diet, producers will be better positioned to protect their animals against diverse health challenges. The extension of Enviva® PRO enhances IFF's robust portfolio of proven, cost-effective animal nutrition and health solutions that help customers optimize production, livability and profitability.
4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)
4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)
4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)
SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)
SC 13G/A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)
SC 13G - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Subject)
CFRA downgraded Intl Flavors from Buy to Sell and set a new price target of $77.00
Argus upgraded Intl Flavors from Hold to Buy
Morgan Stanley upgraded Intl Flavors from Equal-Weight to Overweight and set a new price target of $110.00 from $111.00 previously
DEFA14A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)
DEF 14A - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)
8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)
IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 11, 2025 to shareholders of record as of March 21, 2025. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights R
International Flavors & Fragrances Inc. (NYSE:IFF) reported financial results for the fourth quarter and full year ended December 31, 2024. Full year 2024 Consolidated Summary: Reported (GAAP) Adjusted (Non-GAAP)1 Sales Income Before Taxes EPS Operating EBITDA Operating EBITDA Margin EPS ex Amortization $11.5 B $278 M $0.95 $2.2 B 19.2% $4.31 Management Commentary "IFF delivered a solid performance in 2024, reflecting the hard work and dedication of our global team," said CEO Erik Fyrwald. "Their commitment to serving our customers with industry-leading innovation drove strong top
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2024 earnings results following the market close on Tuesday, Feb. 18, 2025. The management team will host a live webcast on Wednesday, Feb. 19, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company's management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 20, 2025 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay.
4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)
4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)
Alexandra Carlin and Alex Lee join the Paris-based fine fragrance team, bringing fresh artistic perspectives PARIS, Nov. 4, 2024 /PRNewswire/ -- IFF (NYSE:IFF) proudly welcomes Alexandra Carlin as Senior Fine Fragrance Perfumer and Alex Lee as Fine Fragrance Perfumer to its Paris-based team. These strategic additions aim to enhance the Company's creative prowess in the world of perfumery. "We're excited for the talent and creative energy that Alexandra and Alex will bring to IFF Scent," said Sabrya Meflah, president, Fine Fragrance, IFF. "Alexandra's ability to translate deep
NEW YORK, Sept. 26, 2024 /PRNewswire/ -- IFF (NYSE:IFF) Pharma Solutions is proud to announce its more than 75-year legacy as an excipient manufacturer with new product launches and technologies for the pharmaceutical and biotech industries. Celebrating this pivotal milestone, IFF will spotlight its latest solutions for nitrosamine mitigation at CPHI 2024, Milan, Oct. 8-10, booth 6B10. The range includes a new portfolio of low nitrite excipients and ultrapure alginate biopolymers for next-generation therapeutic development. "We are unveiling groundbreaking technologies that re
IFF (NYSE:IFF) today announced the appointment of Margarita Paláu-Hernández to its Board of Directors, effective June 3, 2024. Paláu-Hernández joins as a mutually agreed independent Director in connection with IFF's previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Following the appointment of Paláu-Hernández, the Board will be comprised of 11 members, ten of which are independent. "We are pleased to welcome Maggie to the IFF Board," said Roger Ferguson, lead director of IFF. "Her legal expertise, consumer insights, and her experience in emerging markets will be invaluable to IFF as we continue to execute on our growth and transformation plan to drive in